Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor

by lowes1 on September 23, 2013

Condition:   Non-Small-Cell Lung Cancer
Sponsors:   AstraZeneca;   AstraZeneca
Not yet recruiting – verified September 2013

View full post on ClinicalTrials.gov: “Lung Neoplasms” | updated in the last 30 days

Leave a Comment

Previous post:

Next post: